cagrilintide novo Nordisk presents new Phase III data for next-gen amylin Weight loss: New drug CagriSema
Weight loss: New drug CagriSema leads to 14% weight loss in trial 1 CagriSema 2.4 mg 2.4 mg FDA NDA filing; Novo Nordisk data on file., 2 Garvey WT, Blher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or Cagrilintide vs Retatrutide Compared Dosage Peptide Novo's CagriSema Outshines Semaglutide In Phase III Diabetes Study No change' for CagriSema as Novo ditches single chamber device Another obesity contender just raised the stakes. Novo Nordisk's CagriSema combination delivered around 20% mean weight loss in a large trial. The formula combines semaglutide with cagrilintide, giving the body multiple appetite control
Pay in 4 interest-free payments of $7.14 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7


